Compendium of Cancer Genome Aberrations

Changes

Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations (view source)

Revision as of 16:42, 22 April 2021

1,932 bytes added ,  16:42, 22 April 2021
m
Jennelleh moved page TestPCDtable to Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations without leaving a redirect
Line 1: Line 1: −
'''Table 1 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
+
'''Table 1 - Clinically significant cytogenomic alterations in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. See Table 2 for references and Level 3 evidence. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
 +
{| class="wikitable"
 +
|'''Evidence Level'''
 +
|'''Chromosomal Abnormality'''
 +
|'''Significance­­'''
 +
|'''Genes'''
 +
|-
 +
| rowspan="11" |'''Level 1'''
 +
 
 +
well established evidence in NCCN guideline,
 +
 
 +
WHO criteria, FDA-approved, COG
 +
 
 +
recommendation, or based on large body of publications.
 +
|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)
 +
|Good prognosis
 +
|
 +
|-
 +
|t(4;14)
 +
|Poor prognosis, predicts bortezomib response
 +
|''[[IGH]]''
 +
|-
 +
|t(6;14)
 +
|Good prognosis
 +
|''[[IGH]]''
 +
|-
 +
|t(14;16)
 +
|Poor prognosis
 +
|''[[IGH]]''
 +
|-
 +
|t(11;14)
 +
|Good prognosis
 +
|''[[IGH]]''
 +
|-
 +
|t(14;20)
 +
|Poor prognosis
 +
|
 +
|-
 +
|del(1p)
 +
|Poor prognosis
 +
|
 +
|-
 +
|1q+
 +
|Poor prognosis
 +
|
 +
|-
 +
|del(13q)
 +
|Poor prognosis
 +
|
 +
|-
 +
|16q
 +
|Poor prognosis
 +
|
 +
|-
 +
|del(17p)
 +
|Poor prognosis (Level 1), predicts response (Level 2)
 +
|
 +
|-
 +
| rowspan="27" |'''Level 2'''
 +
 
 +
emerging evidence by one large study or multiple case reports
 +
|1p CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|<nowiki>+2</nowiki>
 +
|Recurrent
 +
|
 +
|-
 +
|del(4q)
 +
|Recurrent
 +
|
 +
|-
 +
|del(5p), 5q+, del(5q)
 +
|Recurrent
 +
|
 +
|-
 +
|6p+
 +
|Recurrent
 +
|
 +
|-
 +
|del(6q)
 +
|Recurrent
 +
|
 +
|-
 +
|7q+
 +
|Recurrent
 +
|
 +
|-
 +
|del(8p)
 +
|Recurrent
 +
|
 +
|-
 +
|8q24.2+
 +
|Recurrent
 +
|''[[MYC]]''
 +
|-
 +
|9p+
 +
|Recurrent
 +
|
 +
|-
 +
|del(10q23.31)
 +
|Recurrent
 +
|''[[PTEN]]''
 +
|-
 +
|11q+
 +
|Recurrent
 +
|
 +
|-
 +
|del(12p) or 12p CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|del(13q32.2)
 +
|Recurrent
 +
|''[[TGDS]]''
 +
|-
 +
|del(14q)
 +
|Good prognosis
 +
|
 +
|-
 +
| 14q CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|16 CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|17 CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|17q25+
 +
|Recurrent
 +
|
 +
|-
 +
|<nowiki>+18</nowiki>
 +
|Recurrent
 +
|
 +
|-
 +
|<nowiki>+19, 19q+</nowiki>
 +
|Recurrent
 +
|
 +
|-
 +
|del(20p)
 +
|Recurrent
 +
|
 +
|-
 +
|<nowiki>+20, 20q+</nowiki>
 +
|Recurrent
 +
|
 +
|-
 +
|del(22)
 +
|Recurrent
 +
|
 +
|-
 +
|22q21+
 +
|Associated with relapse
 +
|''[[PRAME]]''
 +
|-
 +
|del(X), X+, X CN-LOH
 +
|Recurrent
 +
|
 +
|-
 +
|Xq+ in males
 +
|Poor prognosis
 +
|
 +
|}
 +
 
 +
 
 +
'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Chromosome'''
 
|'''Chromosome'''
Line 7: Line 178:  
|'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)'''
 
|'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)'''
 
|'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)'''
 
|'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)'''
−
|'''References'''  
+
|'''References'''
 
|-
 
|-
 
| rowspan="9" |1
 
| rowspan="9" |1
Line 33: Line 204:  
|1p13.2
 
|1p13.2
 
|Loss
 
|Loss
−
|MAG13(kinase), BCL2 like and others
+
|''[[MAGI3]]'', BCL2 like and others
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 42: Line 213:  
|''[[MAN1A2]], [[FAM46C]], [[GDAP2]]''
 
|''[[MAN1A2]], [[FAM46C]], [[GDAP2]]''
 
|Recurrent
 
|Recurrent
−
|2
+
| 2
 
|<ref name=":0" /> <ref name=":1" />
 
|<ref name=":0" /> <ref name=":1" />
 
|-
 
|-
Line 63: Line 234:  
|''[[CKS1B]]'' and ''[[ANP32E]]''
 
|''[[CKS1B]]'' and ''[[ANP32E]]''
 
|Recurrent
 
|Recurrent
−
|1
+
| 1
 
|<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> <ref name=":8" />
 
|<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> <ref name=":8" />
 
|-
 
|-
 
|1q
 
|1q
−
|Gain
+
| Gain
 
|
 
|
 
|Poor prognostic marker
 
|Poor prognostic marker
Line 120: Line 291:  
|4q35.1
 
|4q35.1
 
|Loss
 
|Loss
−
|''[[DCTD]], [[ING2]],'' and others
+
|''[[DCTD]], [[ING2]]'' and others
 
|Recurrent
 
|Recurrent
 
|2
 
|2
Line 127: Line 298:  
| rowspan="6" |5
 
| rowspan="6" |5
 
|5
 
|5
−
|Gain
+
| Gain
 
|
 
|
 
|Recurrent
 
|Recurrent
Line 149: Line 320:  
|5p14.3
 
|5p14.3
 
|Gain
 
|Gain
−
|''CDH12,10''
+
|''[[CDH10]], [[CDH12]]''
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 158: Line 329:  
|
 
|
 
|Recurrent
 
|Recurrent
−
|2
+
| 2
 
|<ref name=":1" /> <ref name=":2" />
 
|<ref name=":1" /> <ref name=":2" />
 
|-
 
|-
 
|5q13.2
 
|5q13.2
 
|Loss
 
|Loss
−
|''[[OCLN]], [[NAIP]]'', and others
+
|''[[OCLN]], [[NAIP]]'' and others
−
|Recurrent
+
| Recurrent
 
|2
 
|2
 
|<ref name=":3" />
 
|<ref name=":3" />
 
|-
 
|-
−
| rowspan="7" |6
+
| rowspan="6" |6
 
|6p
 
|6p
 
|Gain
 
|Gain
Line 210: Line 381:  
|3
 
|3
 
|<ref name=":5" />
 
|<ref name=":5" />
−
|-
  −
|6q16.3
  −
|Loss
  −
|''[[COQR]], [[GRIK2]]''
  −
|Recurrent
  −
|3
  −
|<ref name=":1" />
   
|-
 
|-
 
| rowspan="4" |7
 
| rowspan="4" |7
Line 235: Line 399:  
|7p15.2
 
|7p15.2
 
|Gain
 
|Gain
−
|''[[CBX3]], etc''
+
|''[[CBX3]]'', etc
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 255: Line 419:  
|<ref name=":0" /> <ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|<ref name=":0" /> <ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|-
 
|-
−
|8p23.1
+
| 8p23.1
 
|Loss
 
|Loss
 
|''[[DEFB4]]'' and others
 
|''[[DEFB4]]'' and others
Line 267: Line 431:  
|Recurrent
 
|Recurrent
 
|3
 
|3
−
|<ref name=":5" />  
+
|<ref name=":5" />
 
|-
 
|-
 
|8q
 
|8q
Line 273: Line 437:  
|
 
|
 
|Recurrent
 
|Recurrent
−
|3
+
| 3
 
|<ref name=":1" />
 
|<ref name=":1" />
 
|-
 
|-
Line 284: Line 448:  
|-
 
|-
 
|8q24.3
 
|8q24.3
−
|Gain
+
| Gain
−
|''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), ZNF41, 616, 707'' and ''ZNF517''
+
|''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), [[ZNF41]], [[ZNF517]], [[ZNF616]]'' and ''[[ZNF707]]''
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 298: Line 462:  
|<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|-
 
|-
−
|9p
+
| 9p
 
|Gain
 
|Gain
 
|
 
|
Line 363: Line 527:  
|<ref name=":2" /> <ref name=":6" />
 
|<ref name=":2" /> <ref name=":6" />
 
|-
 
|-
−
|11q13.1/q13.4
+
| 11q13.1/q13.4
 
|Gain
 
|Gain
−
|''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]],'' and ''[[RELT]]''
+
|''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]]'' and ''[[RELT]]''
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 407: Line 571:  
|-
 
|-
 
| rowspan="3" |13
 
| rowspan="3" |13
−
|13q/13
+
| 13q/13
 
|Loss
 
|Loss
 
|
 
|
Line 429: Line 593:  
|-
 
|-
 
| rowspan="5" |14
 
| rowspan="5" |14
−
|14q/14
+
| 14q/14
 
|Loss
 
|Loss
 
|
 
|
Line 511: Line 675:  
|cnLOH
 
|cnLOH
 
|
 
|
−
|Recurrent
+
| Recurrent
 
|2
 
|2
 
|<ref name=":7" />
 
|<ref name=":7" />
Line 530: Line 694:  
|<ref name=":4" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|<ref name=":4" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" />
 
|-
 
|-
−
|17p13
+
| 17p13
 
|Loss
 
|Loss
−
|''[[ATP1B2]], '''[[TP53]]''', [[WRAP5]], [[EFNB3]]''
+
|''[[ATP1B2]], [[TP53]], [[WRAP5]], [[EFNB3]]''
−
|Predictive & prognostic
+
| Predictive & prognostic
 
|1
 
|1
 
|<ref name=":1" /> <ref name=":8" />
 
|<ref name=":1" /> <ref name=":8" />
Line 576: Line 740:  
|19p/ 19p13
 
|19p/ 19p13
 
|Gain
 
|Gain
−
|''ICAM4,ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]],'' and ''[[DNMT1]]''
+
|''ICAM4, ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]]'' and ''[[DNMT1]]''
 
|Recurrent
 
|Recurrent
 
|3
 
|3
Line 635: Line 799:  
| rowspan="8" |X
 
| rowspan="8" |X
 
|X
 
|X
−
|Gain/ Loss
+
|Gain / Loss
 
|
 
|
 
|Recurrent
 
|Recurrent
Line 700: Line 864:  
|Genome wide load of CNA > 100Mb
 
|Genome wide load of CNA > 100Mb
 
|
 
|
−
|gain/loss
+
|Gain / Loss
 
|
 
|
 
|associated with significant change in GEP at relapse
 
|associated with significant change in GEP at relapse
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/8378...10146"